Breaking News, Financial News

Financial Report: Charles River Laboratories

Argenta and BioFocus acquisition drives growth in the quarter

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Charles River Laboratories   3Q Revenues:  $327.6 million (+12%) 3Q Earnings: $32.0 million (+4%) YTD Revenues: $968.1 million (+10%) YTD Earnings: $99.5 million (+19%) Comments: Revenue growth was driven by the acquisition of Argenta and BioFocus, which was completed on April 1, 2014 and contributed 8% to 3Q revenue, as well as double-digit growth in the Manufacturing Support segment. Research Models and Services segment revenue was flat at $124.0 million in the quarter. Discovery and Safet...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters